Suzhou YiaT Biopharma

Suzhou YiaT Biopharma is a clinical-stage biotechnology company dedicated to the development of next-generation antibody-drug conjugates (ADCs) for oncology. Headquartered in the Suzhou Industrial Park, the company utilizes its proprietary YiaT-ADC platform to engineer therapies with improved stability, site-specific conjugation, and optimized linker-payload combinations. Its lead candidate, YT-101, is a Trop2-directed ADC currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. The company's pipeline also includes promising candidates targeting B7-H3 and Nectin-4, aimed at addressing significant unmet needs in cancer care. YiaT Biopharma is led by a team of industry veterans with extensive experience in antibody engineering and drug development from global pharmaceutical companies.